Perrigo Lawsuit: PRGO Defendants Ask Court to Dismiss Investor Claims
TipRanks (Mon, 24-Aug 3:44 PM ET)
Perrigo Targets Streamlined, Focused Growth Despite Revenue Dip and Margin Pressure in Q2 2026
Market Chameleon (Wed, 5-Aug 7:45 AM ET)
Perrigo Reports Second Quarter 2026 Financial Results From Continuing Operations
PRNewswire (Wed, 5-Aug 6:30 AM ET)
Perrigo Announces Quarterly Dividend
PRNewswire (Thu, 30-Jul 8:31 AM ET)
Perrigo to Present at the Canaccord 46th Annual Growth Conference
PRNewswire (Wed, 29-Jul 8:30 AM ET)
Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026
PRNewswire (Wed, 22-Jul 8:30 AM ET)
Perrigo Announces Appointment of Two New Independent Directors to Board
PRNewswire (Tue, 30-Jun 4:26 PM ET)
PRGO Leadership Shake-Up: Board Reaffirms Strategy and 2026 Outlook Amid Sudden CEO Change
Market Chameleon (Tue, 9-Jun 3:33 AM ET)
Perrigo Announces Leadership Transition
PRNewswire (Mon, 8-Jun 4:19 PM ET)
Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference
PRNewswire (Tue, 26-May 8:32 AM ET)
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Perrigo Company PLC trades on the NYSE stock market under the symbol PRGO.
As of August 24, 2026, PRGO stock price climbed to $14.27 with 1,927,370 million shares trading.
PRGO has a beta of 2.56, meaning it tends to be more sensitive to market movements. PRGO has a correlation of 0.26 to the broad based SPY ETF.
PRGO has a market cap of $1.98 billion. This is considered a Small Cap stock.
Last quarter Perrigo Company PLC reported $1 billion in Revenue and $.50 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.14.
In the last 3 years, PRGO traded as high as $38.07 and as low as $9.23.
The top ETF exchange traded funds that PRGO belongs to (by Net Assets): IJR, PEY, IWM, VTI, VB.
PRGO has underperformed the market in the last year with a return of -34.1%, while SPY returned +21.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PRGO shares. However, PRGO has outperformed the market in the last 3 month and 2 week periods, returning +28.3% and +11.1%, while SPY returned +3.1% and -1.3%, respectively. This indicates PRGO has been having a stronger performance recently.
PRGO support price is $13.82 and resistance is $14.68 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRGO shares will trade within this expected range on the day.
